Cargando…

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine

Detalles Bibliográficos
Autores principales:	Liu, J, Ngai, N, Stone, GW, Yue, F, Ostrowski, MA
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767593/ http://dx.doi.org/10.1186/1742-4690-6-S3-P11

Ejemplares similares

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

P02.06. The effect of massage therapy for breast surgery patients
por: Drackley, N, et al.
Publicado: (2012)

P06-02 Physical activity levels of citizens in Dubrovnik, Croatia
por: Škegro, Dario, et al.
Publicado: (2022)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Generation of direct antigen-sandwich enzyme-linked immune-sorbent assays (ELISA) for quantitation of HTLV-1 gp46, p24, Tax and related host cellular antigens OX40, OX40L and CD25
por: Tanaka, Reiko, et al.
Publicado: (2014)

Role of CD40 ligand in transfusion-related acute lung injury
por: Tuinman, PR, et al.
Publicado: (2011)

Evaluation of Latent Membrane Protein 1 as a novel vaccine adjuvant
por: Termini, JM, et al.
Publicado: (2012)

Prevalence analysis of OX40-positive cell populations in solid tumors
por: Ziai, James, et al.
Publicado: (2015)

P02-04. Multimeric soluble CD40 ligand efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus strains
por: Najera, J, et al.
Publicado: (2009)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand
por: Jiang, Hong, et al.
Publicado: (2015)

PA02.06. Tracking the transitions in Guggulu Kalpana : An extensive review through Brihat Trayi and Laghu Trayi
por: Bhapkar, Vedvati
Publicado: (2013)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
por: Ziai, James, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

P06-02. High prevalences of HIV, HCV, HBV and Treponema pallidum in male and trans sex workers from Argentina
por: Farías, M dos Ramos, et al.
Publicado: (2009)

Strong association between hla-a*02:06 and acetaminophen-related stevens-johnson syndrome with severe mucosal involvements in the Japanese
por: Ueta, Mayumi, et al.
Publicado: (2014)

P02-06 Citizen science during Covid-19 pandemic to enhance an activating environment in a low-SES neighborhood
por: Van Holland, Berry, et al.
Publicado: (2022)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

P02.40. A systematic review of measurement properties of mindfulness instruments
por: Park, T, et al.
Publicado: (2012)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine
por: Berrong, Zuzana, et al.
Publicado: (2014)

P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand
por: Melchers, M, et al.
Publicado: (2009)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

P02-11. Correlate of local adjuvanticity and inflammation for experimental vaginal adjuvants in mice
por: Lindqvist, M, et al.
Publicado: (2009)

P02-03. Screening of potential adjuvants for induction of pro-IgA factors
por: Buffa, V, et al.
Publicado: (2009)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
por: Akporiaye, Emmanuel T, et al.
Publicado: (2013)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

P10-10. HIV-1 Gag virus like particles pseudotyped with CD40 ligand to stimulate innate immune responses
por: Köstler, J, et al.
Publicado: (2009)

P06-06. Capacity building for HIV vaccine trials in Africa through South-South collaboration
por: Mpendo, J, et al.
Publicado: (2009)

A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort
por: Bossini-Castillo, L, et al.
Publicado: (2010)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Protection from Hendra virus infection with Canarypox recombinant vaccine
por: Guillaume-Vasselin, Vanessa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i8uk0pc013tq3vc5nj9rbot339